Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Empasiprubart in Polyneuropathy. The expected timing is based on the latest available company guidance and may change.
EMVIGORATE trial. 2/27/25- Registrational study expected to start in H1 2025. 01/12/26:- CIDP Ph3 EMVIGORATE/EMNERGIZE topline data in H2 2027. 03/06/26:- EMVIGORATE and EMNERGIZE Phase 3 CIDP study designs presented at AAN on Apr 19, 2026.
Verification
Confirm timing and program details against the company announcement or filing.